The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

A. Heres Diddens, S. Kraaijenga, V. Coupé, F. Hilgers, L. van der Molen, L. Smeele, V.P. Retèl

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.

Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.

Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.

Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.
Original languageEnglish
Pages (from-to)290-297
Number of pages8
Issue number5
Early online date2016
Publication statusPublished - 3 Sept 2017


  • Temporomandibular disorder
  • Temporomandibular disorder; TheraBite; cost-effectiveness; mandibular function; orofacial pain; physical therapy; quality of life; trismus
  • TheraBite
  • cost-effectiveness
  • mandibular function
  • orofacial pain
  • physical therapy
  • quality of life
  • trismus

Cite this